Galmed Pharmaceuticals (GLMD) Total Debt Growth (3y) (2016 - 2026)
Galmed Pharmaceuticals (GLMD) Total Debt Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.08% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.52% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -22.87% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.30% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.76% |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | -16.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.78% |
| Dec 31, 2025 | 16.39% |
| Jun 30, 2025 | 18.02% |
| Mar 31, 2025 | -14.98% |
| Dec 31, 2024 | -23.07% |
| Sep 30, 2024 | 1.68% |
| Jun 30, 2024 | -36.63% |
| Mar 31, 2024 | -34.09% |
| Dec 31, 2023 | -90.34% |
| Sep 30, 2023 | -11.79% |
| Jun 30, 2023 | -11.39% |
| Mar 31, 2023 | -8.70% |
| Dec 31, 2022 | -17.03% |
| Jun 30, 2022 | -3.13% |
| Mar 31, 2022 | 9.88% |
| Dec 31, 2021 | 4.16% |
| Sep 30, 2021 | 9.42% |
| Jun 30, 2021 | -1.84% |
| Mar 31, 2021 | 79.15% |
| Dec 31, 2020 | 877.58% |